Project Resmain Study

Basic data

Title:
Resmain Study
Duration:
03/07/2017 to 31/12/2019
Abstract / short description:
A multicentre, double blind, randomised, placebo
controlled, Phase II trial to evaluate
Resminostat for maintenance treatment of
patients with advanced stage (Stage IIB IVB)
mycosis fungoides (MF) or Sézary Syndrome
(SS) that have achieved disease control with
systemic therapy – the RESMAIN Study
Keywords:
dermatology
Dermatologie
skin diseases
Hautkrankheiten

Involved staff

Managers

Faculty of Medicine
University of Tübingen
Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine

Contact persons

Universität Tübingen

Local organizational units

Department of Dermatology
Hospitals and clinical institutes
Faculty of Medicine

Funders

Dublin, Ireland
Help

will be deleted permanently. This cannot be undone.